Adjuavnt tyrosinase peptide vaccination in patients with resected stage III/IV melanoma.

被引：0
|
作者：
Letsch, A.
Scheibenbogen, C.
Fluck, M.
Asemissen, A.
Nagorsen, D.
Thiel, E.
Keilholz, U.
机构：
[1] CBF, Charite, Hematol & Oncol, Berlin, Germany
[2] Fachklin Hornheide, Munster, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：117S / 117S
页数：1
相关论文
共 50 条
  • [1] Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma
    Wong, R
    Lau, R
    Chang, J
    Kuus-Reichel, T
    Brichard, V
    Bruck, C
    Weber, J
    CLINICAL CANCER RESEARCH, 2004, 10 (15) : 5004 - 5013
  • [2] A phase I/II study of telomerase peptide vaccination in combination with chemotherapy in patients with stage IV malignant melanoma.
    Aamdal, S.
    Dueland, S.
    Engebraaten, O.
    Owre, K.
    Dyrhaug, M.
    Trachsel, S.
    Gaudernack, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 460S - 460S
  • [3] Toxicities with combination BRAF and MEK inhibition in resected stage III melanoma.
    Warrier, Govind
    Homan, Morgan
    Lao, Christopher D.
    Yentz, Sarah Elizabeth
    Kraft, Shawna
    Fecher, Leslie Anne
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Treatment of patients with inoperable stage III or stage IV melanoma. Societe francaise de dermatologie
    Guillot, B.
    Charles, J.
    Jeudy, G.
    Cupissol, D.
    Dupuy, A.
    Dutriaux, C.
    Gangloff, D.
    Magne, N.
    Mirabe, X.
    M'Sadek, A.
    Pracht, M.
    Sichel, C.
    Do Outeiro, G.
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2018, 145 (6-7): : 413 - 422
  • [5] Utility of PET/CT for surveillance of asymptomatic patients with resected stage III or IV melanoma
    Leon-Ferre, Roberto Antonio
    Kottschade, Lisa A.
    Lowe, Val J.
    Markovic, Svetomir
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] Temozolomide (TMZ) plus thalidomide (THAL) as adjuvant therapy in patients with stage III and stage IV malignant melanoma.
    Hwu, WJ
    Coit, D
    Jaques, D
    Panageas, KS
    Lamb, LA
    Quinn, CJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 728S - 728S
  • [7] Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
    Weber, J.
    Mandala, M.
    Del Vecchio, M.
    Gogas, H. J.
    Arance, A. M.
    Cowey, C. L.
    Dalle, S.
    Schenker, M.
    Chiarion-Sileni, V.
    Marquez-Rodas, I.
    Grob, J-J.
    Butler, M. O.
    Middleton, M. R.
    Maio, M.
    Atkinson, V.
    Queirolo, P.
    Gonzalez, R.
    Kudchadkar, R. R.
    Smylie, M.
    Meyer, N.
    Mortier, L.
    Atkins, M. B.
    Long, G. V.
    Bhatia, S.
    Lebbe, C.
    Rutkowski, P.
    Yokota, K.
    Yamazaki, N.
    Kim, T. M.
    de Pril, V.
    Sabater, J.
    Qureshi, A.
    Larkin, J.
    Ascierto, P. A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (19): : 1824 - 1835
  • [8] Management of resected stage III/IV melanoma with adjuvant immunotherapy.
    Johnson, Rebecca
    Atkinson, Victoria
    Bhave, Prachi
    Weppler, Alison Margaret
    Peters, Geoffrey David
    Abed, Afaf
    Lyle, Megan
    Khattak, Muhammad Adnan
    Haydon, Andrew Mark
    Carlino, Matteo S.
    Sandhu, Shahneen Kaur
    Long, Georgina V.
    Menzies, Alexander M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] ICI for resected stage IV melanoma
    Killock, David
    NATURE REVIEWS CLINICAL ONCOLOGY, 2020, 17 (08) : 450 - 450
  • [10] ICI for resected stage IV melanoma
    David Killock
    Nature Reviews Clinical Oncology, 2020, 17 : 450 - 450
12345